211At-BC8-B10 Followed by Donor Stem Cell Transplant
Phase 1/2
30
about 9.7 years
18–75
1 site in WA
About this study
This trial is testing the safety and best dose of a radioactive agent linked to an antibody (211At-BC8-B10) followed by donor stem cell transplant in treating patients with high-risk acute leukemia or myelodysplastic syndrome that has come back or isn't responding to treatment. The treatment involves giving chemotherapy, total body irradiation, and then donor stem cells to help the patient's bone marrow make new blood cells.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
- 2.Receive Recombinant Granulocyte Colony-Stimulating Factor
- 3.Receive Total-Body Irradiation
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), Antineoplastic Agent [TC] (Nucleic Acid Synthesis Inhibitors), Immunological Agents (Enzyme Inhibitors), colony stimulating factor, tacrolimus
infusion, injection (Injection), injection, intravenous
Primary: Toxicity: Proportion of patients who develop grades III/IV Bearman regimen-related toxicity
Secondary: Disease-free survival, Non-relapse mortality (NRM), Overall survival
biopsy, diagnostic, radiation
Oncology